Recently in a Phase I dose-escalation/expansion study, patients with metastatic EGFR-mutant/NSCLC with prior TKI therapy (including osimertinib) showed clinical benefit following treatment with HER3-DXd (topoisomerase-I inhibitor-based HER3-ADC) [14]. This evidence concerns the gene ERBB3 and non-small cell lung carcinoma.